12:00 AM
 | 
Oct 15, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Kremezin: Phase III data

Top-line data from the double-blind, international Phase III EPPIC-1 and EPPIC-2 trials in about 2,000 patients total with moderate to severe CKD showed that once-daily 9 g AST-120 plus standard of care (SOC) missed the composite primary endpoint of time to initiation of dialysis, kidney transplantation or doubling of...

Read the full 224 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >